LIMINATUS PHARMA, INC. Interest Expense Nonoperating
LIMINATUS PHARMA, INC. (LIMN) reported Interest Expense Nonoperating of $18.84 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-14
- LIMINATUS PHARMA, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $18.84K, a 69.75% decline year-over-year.
- LIMINATUS PHARMA, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $18.64K, a 83.86% decline year-over-year.
- LIMINATUS PHARMA, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $19.05K, a 82.06% decline year-over-year.
- LIMINATUS PHARMA, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $19.05K, a 79.45% decline year-over-year.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.84K 10-Q · filed 2026-08-14 | $37.48K 10-Q · filed 2026-08-14 | $56.53K derived: sum of 3 quarters · filed 2026-08-14 | $75.58K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $18.64K S-1 · filed 2026-06-24 | $37.69K derived: sum of 2 quarters · filed 2026-06-24 | $56.74K derived: sum of 3 quarters · filed 2026-06-24 | $119.03K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $19.05K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $38.10K derived: sum of 2 quarters · filed 2026-06-24 | $100.39K derived: sum of 3 quarters · filed 2026-08-14 | $215.90K S-1 · filed 2026-06-24 |
| 2025-09-30 | $19.05K 10-Q · filed 2025-11-14 | $81.34K derived: sum of 2 quarters · filed 2026-08-14 | $196.85K 10-Q · filed 2025-11-14 | $303.02K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $62.29K 10-Q · filed 2026-08-14 | $177.80K 10-Q · filed 2026-08-14 | $283.96K derived: sum of 3 quarters · filed 2026-08-14 | $376.67K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $115.51K S-1 · filed 2026-06-24 | $221.68K derived: sum of 2 quarters · filed 2026-06-24 | $314.38K derived: sum of 3 quarters · filed 2026-06-24 | $391.60K derived: sum of 4 quarters · filed 2026-06-24 |
| 2024-12-31 | $106.16K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $198.87K derived: sum of 2 quarters · filed 2026-06-24 | $276.09K derived: sum of 3 quarters · filed 2026-06-24 | $338.88K S-1 · filed 2026-06-24 |
| 2024-09-30 | $92.71K 10-Q · filed 2025-11-14 | $169.93K derived: sum of 2 quarters · filed 2025-11-14 | $232.72K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $77.22K 10-Q · filed 2025-10-06 | $140.01K 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |